Application effect of intravenous thrombolysis with recombinant tissuetype plasminogen activator combined with interventional therapy in patients with acute ischemic stroke
SUN Yongjin PIAO Xiangyu
Department of Neurology,Zhongshan Hospital Affiliated to Dalian University,Liaoning Province,Dalian 116001,China
Abstract：Objective To investigate the application effect of intravenous thrombolysis with recombinant tissue-type plasminogen activator combined with interventional therapy in patients with acute ischemic stroke.Methods A total of 100 patients with acute ischemic stroke in Zhongshan Hospital Affiliated to Dalian University from January 2018 to may 2021 were selected as the research object.They were divided into the control group (50 cases) and the observation group (50 cases) according to the random number table method.The patients in the control group received intravenous thrombolysis with recombinant tissue-type plasminogen activator,the patients in the observation group received intravenous thrombolysis with recombinant tissue-type plasminogen activator combined with interventional therapy.The clinical efficacy,the severity of dysfunction (modified Rankin scale [MRS]),the ability of self-care (modified Barthel index [MBI]),the level of cerebral hemodynamics before and after treatment and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant (P＜0.05).Before treatment,there were no significant differences in the MRS score,MBI score,cerebral blood flow velocity,minimum blood flow and dynamic impedance between the two groups (P＞0.05).After treatment,the MRS score of the observation group was lower than that of the control group,the MBI score,cerebral blood flow velocity,minimum blood flow and dynamic impedance in the observation group were higher than those in the control group,the differences were statistically significant (P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05).Conclusion Intravenous thrombolytic therapy with recombinant tissue-type plasminogen activator combined with interventional therapy has a good effect on patients with acute ischemic stroke,which can significantly improve their functional disorders and cerebral hemodynamic indexes,and promote the recovery of self-care ability,with fewer adverse reactions,and has a higher clinical promotion value.
京公网安备 11010502046607号